|
|
Efficacy and mechanism of antibiotics combined with Kangfuyan capsules for treating patients with chronic endometritis based on Toll-like receptor-nuclear factor κB signaling pathway |
1.Tunchang People's Hospital, Tunchang, Hainan Province, 571600;2.The Second Affiliated Hospital of Hainan medical University |
|
|
Abstract To investigate the efficacy and mechanism of antibiotics combined with Kangfuyan capsules for treating patients with chronic endometritis (CE) based on Tolllike receptor-nuclear factor κB (TLRs-NF-κB) signaling pathway. Methods: 92 patients with CE were selected and were randomly divided into two groups according to the ratio of 1:1 from January 2021 to January 2022. 46 patients in the control group were given routine antibiotic treatment, and 46 patients in the observation group were given antibiotics combined with Kangfuyan capsules. The clinical efficacy, the mRNA expressions of TLR2, TLR4, and NF-κB in peripheral blood mononuclear cells (PBMCs) before and after treatment, and the levels of serum TLRs-NF-κB-related inflammatory factors, such as tumor necrosis factor-α (TNF-α), interferon gamma (IFN-γ), interleukin-1β (IL-1β), IL-6, and IL-8 of the patients were compared between the two groups. Results: After 1 week and 2 weeks of treatment, the TCM syndrome scores of the patients in both groups had decreased significantly, and which (6.45±1.14 points and 4.33±0.81 points) of the patients in the observation group were significantly lower than those (7.59±1.22 points and 5.16±1.23 points) of the patients in the control group (P<0.05). The mRNA levels of TLR2, TLR4 and NF-κB in PBMCs and the levels of serum TNF-α, IFN-γ, IL-1β, IL-6, and IL-8 of the patients in the two groups had decreased significantly, and which of the patients in the observation group were significantly lower than those of the patients in the control group (P<0.05). The cure rate (78.3%) of the patients in the observation group was significantly higher than that (58.7%) of the patients in the control group, and the recurrence rate (2.8%) of CE of the patients in the observation group in 6 months of follow-up after operation was significantly lower than that (14.8%) of the patients in the control group (P<0.05). The total effective rate (100.0% vs.95.7%) of the patients in the two groups had no significant difference (P>0.05). Conclusion: Antibacterial drugs combined with Kangfuyan capsules for treating patients with CE can improve the clinical efficacy and reduce the risk of CE recurrence, and the mechanism of which may be related to regulating the TLRs-NF-κB signaling pathway and inhibiting the expression of its downstream inflammatory factors.
|
|
|
|
|
|
|
|